ADC Therapeutics SA (ADCT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-10

Key Insights

ADC Therapeutics reported its Q4 2025 and full-year 2025 financial results, providing an update on the company's operations and financial performance.
The company's revenue and earnings figures for the quarter and year appear to be in line with market expectations, suggesting a stable financial performance.
There were no major announcements or updates regarding the company's pipeline or regulatory milestones, indicating a relatively quiet quarter from a business development standpoint.

Want the newest filings?

This analysis covers the filing from 2026-03-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-12

The company filed an 8-K report on January 12, 2026, providing an updated corporate presentation.
The company's common shares are traded on the New York Stock Exchange under the ticker symbol ADCT.
The company is based in Epalinges, Switzerland and its telephone number is +41 21 653 02 00.

Filed: 2026-01-08

ADC Therapeutics provided preliminary Q4 and FY 2025 revenue estimates, indicating strong financial performance in the period.
The company reported strong cash and cash equivalents as of December 31, 2025, suggesting a solid liquidity position.
Investors should note that the reported financial figures are preliminary and unaudited, and the final audited results may differ.

Other reports for ADC Therapeutics SA

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.